Celularity CEO Comments on Centers for Medicare & Medicaid Services Withdrawal of Skin Substitute Local Coverage Determinations
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage…
Hexaware Comments on Meritless Patent Lawsuit Filed by Natsoft
MUMBAI, India, ISELIN, N.J. and LONDON, Oct. 28, 2025 /PRNewswire/ -- Hexaware…
UK National Martial Arts Governing Body Responds to President Trump’s Autism Comments
Tuesday 23 September, 2025 London, UK - In a recent statement that…
